Physician profile
Jack A Birnbaum
NPI 1801845268
$11,899.74
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,703 · 2020: $1,286 · 2021: $2,033 · 2022: $2,892 · 2023: $1,849 · 2024: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.58 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,769.67 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,526.56 | 2019-2023 | Jardiance, Glyxambi, Synjardy |
| Novo Nordisk INC | $1,437.35 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,153.46 | 2019-2023 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $923.05 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $561.50 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $509.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $409.60 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.77 | 2021-2023 | |
| Corcept Therapeutics | $259.30 | 2020-2023 | Korlym |
| Dexcom, INC. | $257.98 | 2019-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $242.35 | 2019-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $230.15 | 2020-2023 | Gvoke Hypopen |
| Lifescan, INC. | $226.67 | 2020-2023 | |
| Abbott Laboratories | $215.82 | 2019-2023 | Freestyle Libre 3 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Birnbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.